These results suggest that combination treatment with lapatinib and ipatasertib could be effective against PIK3CA-mutant HER2+ breast cancers, overcoming the therapeutic difficulty in the currently-used cancer drugs against these cancers. The gene discussed is ERBB2; the disease is breast cancer.